相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
Mario Annunziata et al.
FRONTIERS IN ONCOLOGY (2020)
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
Koji Sasaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
Akiko Ogata et al.
PLOS ONE (2019)
Is There a Role for Dose Modification of TKI Therapy in CML?
M. Copland
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
Monica Crugnola et al.
ANNALS OF HEMATOLOGY (2019)
Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors
Roberto Latagliata et al.
BLOOD (2019)
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Preetesh Jain et al.
BLOOD ADVANCES (2019)
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
Nanxin Li et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients
Preetesh Jain et al.
CANCER (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Koji Sasaki et al.
CANCER (2016)
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction
Koji Sasaki et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
Roberto Latagliata et al.
NEOPLASIA (2016)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain et al.
LANCET HAEMATOLOGY (2015)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival
Massimo Breccia et al.
LEUKEMIA RESEARCH (2014)
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study
Roberto Latagliata et al.
DRUGS & AGING (2013)
分享论文
